Atherogenic lipoprotein phenotype (ALP) is a common autosomal dominant trait characterized by decreased HDL-cholesterol, moderately raised triglycerides, increased levels of small, dense LDL, and a two-to four-fold increased risk of myocardial infarction. ALP is treated through employing fenofibrate which is used for increasing the LDL clearance and reducing small and dense LDL elevated levels.
Atherogenic lipoprotein phenotype (ALP) is linked to ATHS gene, which is similar to LDLR gene. The magnitude of risk for ALP was found to robustly depend on the overall plasma concentrations of apolipoprotein (apo) B-containing lipoproteins, which demonstrated the necessity of considering the quality and quantity of LDL subfractions for the estimation of atherosclerosis risk.